These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30478166)

  • 1. SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [
    Wring S; Borroto-Esoda K; Solon E; Angulo D
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus.
    Wring S; Murphy G; Atiee G; Corr C; Hyman M; Willett M; Angulo D
    Clin Pharmacol Drug Dev; 2019 Jan; 8(1):60-69. PubMed ID: 29947477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.
    Wring S; Murphy G; Atiee G; Corr C; Hyman M; Willett M; Angulo D
    J Clin Pharmacol; 2018 Oct; 58(10):1305-1313. PubMed ID: 29746713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.
    Scorneaux B; Angulo D; Borroto-Esoda K; Ghannoum M; Peel M; Wring S
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.
    Wring SA; Randolph R; Park S; Abruzzo G; Chen Q; Flattery A; Garrett G; Peel M; Outcalt R; Powell K; Trucksis M; Angulo D; Borroto-Esoda K
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
    Apgar JM; Wilkening RR; Parker DL; Meng D; Wildonger KJ; Sperbeck D; Greenlee ML; Balkovec JM; Flattery AM; Abruzzo GK; Galgoci AM; Giacobbe RA; Gill CJ; Hsu MJ; Liberator P; Misura AS; Motyl M; Nielsen Kahn J; Powles M; Racine F; Dragovic J; Fan W; Kirwan R; Lee S; Liu H; Mamai A; Nelson K; Peel M
    Bioorg Med Chem Lett; 2021 Jan; 32():127661. PubMed ID: 33160023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
    Spec A; Pullman J; Thompson GR; Powderly WG; Tobin EH; Vazquez J; Wring SA; Angulo D; Helou S; Pappas PG;
    J Antimicrob Chemother; 2019 Oct; 74(10):3056-3062. PubMed ID: 31304536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.
    Lepak AJ; Marchillo K; Andes DR
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1265-72. PubMed ID: 25512406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.
    Pfaller MA; Messer SA; Rhomberg PR; Borroto-Esoda K; Castanheira M
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.
    Larkin E; Hager C; Chandra J; Mukherjee PK; Retuerto M; Salem I; Long L; Isham N; Kovanda L; Borroto-Esoda K; Wring S; Angulo D; Ghannoum M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223375
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.
    Wiederhold NP; Najvar LK; Jaramillo R; Olivo M; Pizzini J; Catano G; Patterson TF
    J Antimicrob Chemother; 2018 Feb; 73(2):448-451. PubMed ID: 29177447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Second-Generation Fungerp Analog, SCY-247, Shows Potent
    Chu S; Long L; Sherif R; McCormick TS; Borroto-Esoda K; Barat S; Ghannoum MA
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33317999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Second-Generation Fungerp Analog, SCY-247, Shows Potent
    Chu S; Long L; McCormick TS; Borroto-Esoda K; Barat S; Ghannoum MA
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species.
    Ong V; James KD; Smith S; Krishnan BR
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.
    Lamoth F; Alexander BD
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4308-11. PubMed ID: 25896696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.
    Lee A; Prideaux B; Zimmerman M; Carter C; Barat S; Angulo D; Dartois V; Perlin DS; Zhao Y
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
    Marcos-Zambrano LJ; Gómez-Perosanz M; Escribano P; Bouza E; Guinea J
    J Antimicrob Chemother; 2017 Jul; 72(7):1969-1976. PubMed ID: 28175309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug development challenges and strategies to address emerging and resistant fungal pathogens.
    McCarthy MW; Walsh TJ
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):577-584. PubMed ID: 28480775
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Berkow EL; Angulo D; Lockhart SR
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483955
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.